polyepitope neoantigen dna vaccine

A polyepitope neoantigen DNA vaccine is a personalized cancer immunotherapy platform that encodes multiple neoantigen epitopes—tumor-specific mutated peptide sequences—using a DNA plasmid. This DNA is delivered intramuscularly, usually by electroporation, to promote uptake and expression in host cells. The vaccine design typically integrates long (≥20 amino acid) patient-specific neoantigens, often fused to a mutant ubiquitin to enhance antigen processing and presentation. The resulting expressed antigens stimulate the immune system to generate neoantigen-specific CD4+ and CD8+ T cell responses, enabling the immune system to target and attack cancer cells with corresponding mutations. The vaccine is manufactured individually for each patient based on genomic sequencing and bioinformatic analysis of their tumor, and has shown robust immunogenicity and safety in preclinical models and early phase 1 clinical trials, particularly in cancers such as triple-negative breast cancer and pancreatic cancer[1][2][3][5][6].

Other names

personalized polyepitope neoantigen dna vaccineneoantigen dna vaccinepolyepitope dna vaccine